Insmed Inc. Stock
Price
Target price
?
?
-0.060%
-0.06
-0.060%
€172.10
09:32 / Stuttgart Stock Exchange
WKN: A1JJA3 / Symbol: INSM / Name: Insmed / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Insmed Inc. Stock
With only a change of -€0.060 (-0.060%) the Insmed Inc. price is nearly unchanged from yesterday.
The stock is one of the favorites of our community with 62 Buy predictions and 1 Sell predictions.
With a target price of 172 € there is a hugely positive potential of 70.4% for Insmed Inc. compared to the current price of 100.94 €.
Our community identified positive and negative aspects for Insmed Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Insmed Inc. stock. On the other hand our users think that "Return on equity" could be a problem in the future.
Pros and Cons of Insmed Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
B****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Insmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Insmed Inc. | -0.060% | 3.505% | 21.482% | 23.171% | -31.757% | 451.913% | 324.370% |
| Evolus Inc | -2.150% | -3.417% | 3.222% | -27.925% | 5.798% | -11.969% | -44.019% |
| Heron Therapeutics Inc. | -4.440% | 0.915% | 5.753% | -80.294% | -66.338% | -68.750% | -96.867% |
| Rhythm Pharmaceuticals | -1.580% | -3.553% | 25.828% | 27.517% | 1.604% | 573.759% | 479.268% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01
When examining the financials of Insmed (INSM), a player in the Biotechnology & Medical Research sector, it's essential to approach the numbers with a blend of cautious optimism and critical scrutiny. Insmed shows significant promise in terms of market capitalization and revenue growth potential, but several challenges lurk beneath the surface, particularly regarding profitability and high debt levels. Let’s dig deeper to uncover the various facets of Insmed’s financial health.
Pros of Insmed’s Financials
Market Capitalization: With a market capitalization of approximately $11 billion, Insmed positions itself as a notable player within its industry. A high market cap often signals investor confidence and robust business potential.
Comments
Insmed (INSM) had its "buy" rating reaffirmed by Guggenheim. They now have a $207.00 price target on the stock.
Show more
Ratings data for INSM provided by MarketBeat
Insmed (INSM) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
Show more
Ratings data for INSM provided by MarketBeat
Insmed (INSM) had its price target lowered by JPMorgan Chase & Co. from $180.00 to $179.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for INSM provided by MarketBeat
News
Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus
Key Points
- Interested in Insmed, Inc.? Here are five stocks we like better.
- Insmed defended the BRINSUPRI launch after investors worried about discontinuation rates, saying the drug’s $208
